

Appl. No. 10/888,962  
Response Dated September 26, 2006  
Reply to Office Action of March 28, 2006

RECEIVED  
CENTRAL FAX CENTER  
SEP 26 2006

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-32 (cancelled).

Claim 33 (New): A method of reducing immune coagulation associated with fgl2 expression comprising administering, to an animal in need thereof, an effective amount of an antisense oligonucleotide that is complementary to a sequence in the promoter region of fgl2 which comprises nucleotides 957 to 1023 of SEQ ID NO:1, wherein the antisense oligonucleotide inhibits fgl2 expression thereby reducing immune coagulation.

Claim 34 (New): The method according to claim 33 wherein the oligonucleotide sequence consists of 8 nucleotides and is complementary to an 8 nucleotide consecutive sequence in the nucleotide sequence 957 to 1023 of SEQ ID NO:1.

Claim 35 (New): The method according to claim 33 wherein the oligonucleotide sequence comprises a sequence that is complementary to a sequence in the LF-A1 binding element of the promoter region of the fgl2 gene which comprises nucleotides 997 to 1004 of SEQ ID NO:1.

Claim 36 (New): The method according to claim 33 wherein the animal is infected with a hepatitis virus.

Claim 37 (New): The method of claim 34 wherein the hepatitis virus is selected from the group consisting of MHV-3 and MHV-A59.